Research Grade Teclistamab (DHF92402)

Catalog No.

DHF92402

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG4-lambda

Clonality

Monoclonal

Target

Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain

Concentration

1.2 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q02223 & P07766

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific, BCMA, JNJ-64007957, JNJ-7957, Ab-957, CAS: 2119595-80-9

Clone ID

Teclistamab

Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma, PMID: 32956453

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma, PMID: 33227097

MajesTEC results with teclistamab in RRMM, PMID: 34453130

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study, PMID: 34388396

A BCMA-Targeted Bispecific Antibody Is Active in Multiple Myeloma, PMID: 34417227

Document Download

Research Grade Teclistamab.pdf